On (b)(6) 2020 the patient received treatment with liposorber la-15 system.The treatment was completed.At 4:00pm the patient was admitted to the hospital for anasarca with worsening aki exacerbated by dehydration in the setting of elevated cyclosporine levels.The site noted that the sae is possibly related to the treatment and that the device did not malfunction.On (b)(6) 2020, the site reported the sae, classified the adverse event as serious, and noted that the patient was still hospitalized.On 11/30/2020, user facility reported la-15 system lot and serial numbers.They reported that the adverse event has ended on (b)(6) 2020, and that the patient would be continuing treatment with the liposorber system.User facility reported actions taken to treat adverse event as the following medications; cyclosporine held, fluconazole held, lasix oral and iv, and 25% albumin.Mfr#: 3002808904-2020-00021.
|